首页 | 本学科首页   官方微博 | 高级检索  
     

雷贝拉唑联合马来酸曲美布汀治疗反流性食管炎
引用本文:邢开慧,马方兰. 雷贝拉唑联合马来酸曲美布汀治疗反流性食管炎[J]. 西部医学, 2008, 20(2): 315-316
作者姓名:邢开慧  马方兰
作者单位:西昌市人民医院消化内科,四川,西昌,615000
摘    要:目的观察雷贝拉唑联合马来酸曲美布汀治疗反流性食管炎(RE)的临床疗效和安全性。方法将112例RE患者随机分为A、B两组,每组各56例,两组均予马来酸曲美布汀100mg,3次/d,A组加服雷贝拉唑20mg,1次/d,B组加服雷尼替丁150mg,2次/d,分别于治疗前、治疗后4、8周观察临床症状及胃镜变化。结果治疗后4、8周A组的临床症状改善、胃镜检查食管粘膜病损愈合率均优于B组(P〈0.01)。结论雷贝拉唑联合马来酸曲美布汀治疗RE疗效明显优于雷尼替丁联合马来酸曲美布汀。

关 键 词:反流性食管炎  雷贝拉唑  马来酸曲美布汀
文章编号:1672-3511(2008)02-0315-02
修稿时间:2007-11-20

Rabeprazole and Trimebutine for treatment of reflux esophagitis
XING Kai-hui,MA Fang-lan. Rabeprazole and Trimebutine for treatment of reflux esophagitis[J]. , 2008, 20(2): 315-316
Authors:XING Kai-hui  MA Fang-lan
Affiliation:(Department of Gastroenterology, People's Hospital of Xichang, Xichang 615000, Sichuan, China)
Abstract:Objective To investigate the efficacy and safety of Rabeprazole and Trimebutine in the treatment of reflux esophagitis(RE). Methods 112 cases of RE were randomized to 2 groups: group A group B with 56 cases in each group. Both groups were treated with Trimebutine, 100 mg three times daily. Group A were added with Rabeprazole 20mg once daily. Group B were added with Ranitidine 150mg twice daily. Clinical manifestations and gastroscopy results were observed before and 4 weeks, 8 weeks after treatment. Results The total effective rate and the healing rate of esophageal mucosal lesion in group A was higher than that of group B at 4 and 8 weeks after treatment (P〈0. 01). Conclusion The efficacy of Rabeprazole and Trimebutine in the treatment of RE is better than that of Ranitidine and Trimebutine.
Keywords:Reflux esophagitis  Rabeprazole  Trimebutine
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号